title: Changes of expression of glucose transporters in the fetal lamb brain   after MCI-186 administration to the maternal circulation with 10-min   persistent umbilical cord occlusion.
abstract: OBJECTIVE
  To evaluate the effect of MCI-186 (3-methyl-1-phenyl-2-pyrazoline-5-one), a potent hydroxyl radical scavenger, administered to the maternal circulation following umbilical cord occlusion in regard to glucose transporter (GLUT) expression.
  
  
  METHODS
  Fourteen instrumented lambs were prepared. In three cases, a 10-min persistent umbilical cord occlusion was performed; 30 min after the insult, fetal brains were extirpated (Group A). Four cases had a 10-min occlusion(Group B) and four cases had 10-min occlusion and were administered MCI-186 to the maternal circulation (Group C).Three days following the insult, the fetal brains were extirpated. The remaining three cases had a sham operation (Group D).Brain tissue sections were stained at the locations of GLUT-1, -3 and -5 and were evaluated by two pathologists.
  
  
  RESULTS
  The expression of GLUT-1 and -3 significantly increased in the basal ganglia, hippocampi and periventricular region of Group B when compared with that of Group A. The expression of GLUT-1 and -3 in three regions of Group B were significantly higher than that of Group C and D. GLUT-5 was recognised only in Group B.
  
  
  CONCLUSIONS
  On the basis of expression of GLUT, the protective effect of MCI-186 on brain injury resulting from hypoxia/ ischemia-reperfusion is documented.
authors.affiliation: Department of Obstetrics and Gynecology, Tokyo Womnen's Medical University Yachiyo Medical Center, 477-96 Owada-Shinden, Yachiyo Chiba 276-8524, Japan.
authors.forename: Masao
authors.initials: M
authors.lastname: Watanabe
authors.forename: Naoki
authors.initials: N
authors.lastname: Masaoka
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Masaji
authors.initials: M
authors.lastname: Nagaishi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Yamamoto
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001157:Arterial Occlusive Diseases / Q000473:pathology*; D001921:Brain / Q000187:drug effects* / Q000196:embryology / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D000077553:Edaravone; D005260:Female; D005333:Fetus / Q000187:drug effects / Q000378:metabolism; D016166:Free Radical Scavengers / Q000008:administration & dosage; D051246:Glucose Transport Proteins, Facilitative / Q000378:metabolism*; D020925:Hypoxia-Ischemia, Brain / Q000378:metabolism / Q000517:prevention & control; D007275:Injections, Intravenous; D008431:Maternal-Fetal Exchange / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000008:administration & dosage; D021041:Placental Circulation / Q000187:drug effects; D011247:Pregnancy; D015427:Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control; D012756:Sheep; D013997:Time Factors; D014470:Umbilical Cord / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology
chemical_list: D016166:Free Radical Scavengers; D051246:Glucose Transport Proteins, Facilitative; D018696:Neuroprotective Agents; D000077553:Edaravone; D000983:Antipyrine